Changes in heterosubtypic antibody responses during the first year of the 2009 A(H1N1) influenza pandemic. by Freidl, G.S. (Gudrun) et al.
1Scientific RepoRts | 6:20385 | DOI: 10.1038/srep20385
www.nature.com/scientificreports
Changes in heterosubtypic 
antibody responses during the first 
year of the 2009 A(H1N1) influenza 
pandemic
Gudrun S. Freidl1,2, Henk-Jan van den Ham1, Maciej F. Boni3,4, Erwin de Bruin1,2 & 
Marion P.G. Koopmans1,2
Seropositivity to avian influenza (AI) via low-level antibody titers has been reported in the general 
population and poultry-exposed individuals, raising the question whether these findings reflect true 
infection with AI or cross-reactivity. Here we investigated serological profiles against human and avian 
influenza viruses in the general population using a protein microarray platform. We hypothesized 
that higher antibody diversity across recent H1 and H3 influenza viruses would be associated with 
heterosubtypic reactivity to older pandemic- and AI viruses. We found significant heterogeneity in 
antibody profiles. Increased antibody diversity to seasonal influenza viruses was associated with 
low-level heterosubtypic antibodies to H9 and H7, but not to H5 AI virus. Individuals exposed to the 
recent 2009 A(H1N1) pandemic showed higher heterosubtypic reactivity. We show that there is a 
complex interplay between prior exposures to seasonal and recent pandemic influenza viruses and the 
development of heterosubtypic antibody reactivity to animal influenza viruses.
Influenza virus infection triggers the generation of antibodies as part of the humoral component of the host 
immune response. These antibodies, produced by specialized B-cells, are predominantly directed against the 
surface protein hemagglutinin (HA), and to a lesser extent, the neuraminidase (NA) and internal structures, such 
as the nucleoprotein and the matrix proteins1. HA and NA are used to classify influenza viruses into different 
subtypes. The 16 currently known HA-subtypes, originating from birds, divide into two phylogenetic groups 
based on their amino-acid composition, and these further segregate into 5 clades. Group 1 consists of three 
clades spanning ten HA-subtypes (H1, H2, H5, H6; H8, H9, H12; H11, H13, H16), whereas HA-subtypes H3, 
H4, H14 and H7, H10, H15 form the two clades of group 2 2,3. The HA consists of three monomers forming the 
variable globular head (HA1), which contains the receptor-binding site, and the more conserved stem region 
(HA2). The HA protein plays an important role in infection of host cells through the release of viral RNA into 
the host cell by means of membrane fusion4. Antibodies targeting influenza viruses can have neutralizing- or 
non-neutralizing ability. Non-neutralizing antibodies play a vital role in the immune response by e.g., inducing 
phagocytosis, complement-mediated lysis or antibody dependent cellular cytotoxicity (ADCC)5. Neutralization 
of influenza viruses can be achieved in two ways; either by blocking the receptor-binding pocket located in the 
HA1, or by preventing conformational changes in a region involved in membrane fusion, mainly formed by 
HA26. The majority of antibodies target the HA17. However, antibodies binding to the HA2 are able to neutral-
ize various subtypes, reduce virus replication and contribute to a faster recovery8. Immunoglobulins targeting 
structures conserved among subtypes are termed as ‘cross-reactive’. A number of broadly reactive intra-subtype-, 
intra-clade-, intra-group- and inter-group specific neutralizing human and mouse monoclonal antibodies tar-
geting the globular head- or the stem region of the HA have been identified (reviewed by Laursen and Wilson9). 
Their possible role in influenza virus infection has become an area of considerable interest since the occurrence of 
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the most recent H1N1 influenza pandemic in 2009 [A(H1N1)pdm09]. Hancock et al.10 investigated whether sea-
sonal, trivalent influenza vaccines are able to induce cross-reactive antibodies against the A(H1N1)pdm09 virus 
but did not find such antibodies after vaccination10. However, the authors reported on no or little pre-existing 
antibodies in individuals younger than 30 years of age, whereas in older adults some degree of neutralizing or 
cross-reactive antibody concentrations was detected in samples collected before the onset of A(H1N1)pdm09 
circulation10. Wrammert et al.11 studied the serological response after natural infection with A(H1N1)pdm09 
in humans and postulated that broadly cross-reactive antibodies targeting epitopes conserved between different 
influenza virus strains were induced via the activation memory B-cells. The detected antibodies predominantly 
targeted the HA2 and to a lesser extent HA1 of pre-pandemic H1 strains. Broadly H1N1-neutralizing antibodies 
also cross-reacted with avian subtype A(H5N1)11. These and subsequent studies showed that cross-reactive anti-
bodies are boosted when infection occurs with a significantly mismatched HA12.
The effects of broadly-reactive influenza antibodies have not been studied extensively. Specifically, it is 
unknown if broadly reactive antibodies have any neutralizing effect during an avian influenza (AI) virus infection 
or if they generate false positive results in seroepidemiological studies on AI viruses. Zoonotic AI viruses pose 
a threat to public health; for instance, the highly pathogenic (HP) A(H5N1) subtype first crossed the species 
barrier into humans in 199713,14. Since then, more than 800 human infections of A(H5N1) have been reported 
to the World Health Organization, of which 53% succumbed to the disease15. In recent years, additional HP and 
low pathogenic (LP) AIs have expanded the list of zoonotic subtypes causing incidental infection, e.g. LP H9N2, 
H6N2, H10N8, as well as various HP and LP H7 strains. Until recently, H7 strains were associated with mild 
symptoms in humans16 but in March 2013 a novel LPAI subtype (H7N9) emerged in China and has caused three 
waves of human infection associated with severe symptoms and a high case fatality rate17,18. Case fatality rates 
can be inflated if they only capture the most severe cases while mild or subclinical cases are underreported19,20. 
Sero-epidemiological studies are a useful way to shed light on the true extent of a population’s exposure to a par-
ticular virus. A number of serological studies have put forth evidence of human exposure to AIs in humans that 
work with animals21–27 as well as in putatively non-poultry-exposed control groups28,29. These findings pose the 
important question of whether serological reactivity against AI virus antigens reflects true exposure or is caused 
by cross-reactive antibodies.
In the present study, we investigated serological profiles against different human and AI virus subtypes during 
the course of the 2009 pandemic in a group of healthy childbearing age women via neonatal heelprick filter cards. 
Cards were collected continuously over a 100-week period employing a continuous collection study design30. 
Samples were analysed by means of a protein microarray comprising recombinant proteins representing the glob-
ular head domain (HA1) of various influenza virus HAs, as described previously30. Vaccination history of the 
mothers was unknown. Understanding serological profiles of healthy humans can help in distinguishing hetero-
subtypic antibody reactivity from serological response triggered by true infection.
Here, we hypothesized that the profile of antibody reactivities to a range of recent human influenza viruses 
could be used to explain the presence of cross-reactive antibodies to AI antigens (H5, H7 and H9). We found evi-
dence that supported this hypothesis and showed that cross-reactive antibody levels to AI and ancient influenza 
virus subtypes significantly increased after the onset of the 2009 H1N1 pandemic.
Results
Exploratory analysis. Characteristics of the study population are shown in Table 1. The majority of samples 
collected through the heel prick-screening program were submitted from countries located in the northern hem-
isphere (n = 6896), with only 688 samples collected in the southern hemisphere. Submission periods differed per 
country and covered the time span from week 40 in 2008 to week 34 in 2010 (Table 1).
The highest antibody levels were directed to seasonal H1 and H3 antigens, as expected (Fig. 1a, blue). Elevated 
signals against antigen H1.09 were observed (Fig. 1b), and their levels were clearly associated with the onset of the 
pandemic in the second half of the study (Fig. 1b). Similarly, raised signals against 1918-lineage influenza strains 
(H1.18, H1.33) were associated with pandemic onset (see supplementary material S1), as the H1.18 antigen is 
known to be antigenically similar to A(H1N1)pdm0931. In 1957 subtype H2N2 (represented by antigen H2.57) 
caused the second major human pandemic of the 20th century. In 1968 – before the mothers of our study subjects 
were born – H2N2 ceased circulating in the human population32. Nevertheless, antibody signals to this antigen 
were raised, albeit at significantly lower levels compared to reactivity against recent H1 and H3 antigens (Fig. 1a, 
red; Wilcoxon signed rank test, p-values < 0.001). Antibody signals to H9.99 were similarly raised as those against 
H2.57 (Wilcoxon signed rank test: p-value = 0.15). Fluorescence levels against H9.07 and H7.03, although also 
elevated, were significantly lower compared to H2.57 (Wilcoxon signed rank test, p-values < 0.001). Reactivity 
against these AI antigens was most likely caused by cross-reactive antibodies33,34. No noteworthy reactivity against 
H5-antigens was found (Fig. 1a, green).
Antibody diversity across human influenza HA1 antigens and its relation with heterosubtypic 
reactivity. To examine antibody diversity in our study subjects, we introduced the adapted Shannon diver-
sity index (ASDI; see Methods and supplementary material), which aims to represent the number of antigens to 
which an individual has a high titer response. The influenza antigens included in the ASDI measure represented 
recent seasonal influenza viruses H1.99, H1.07, H3.03 and H3.07. ASDI values were calculated per individual and 
ranged from 0.64 to 4.0, with a value of 4.0 meaning that the individual had high titer responses to all four anti-
gens in the ASDI measurement. We arbitrarily divided the ASDI range into four categories to assess correspond-
ing serological profiles and investigate the association between heterosubtypic responses and increasing ASDI. 
The majority (~77%) of individuals had antibody signals to 1.5 to 3.5 antigens (ASDI categories 2&3; Table 1). 
The category with lowest diversity (0–1.5; n = 416) was characterized by the lowest level of H3 responses when 
compared to other ASDI categories and comprised slightly raised signals to H1.18 and H1.09 antigens (Fig. 2). A 
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similar pattern was observed for category two (1.5–2.5; n = 2548) with predominant seasonal H3 signals, together 
with somewhat elevated seasonal and pandemic H1 responses. We also observed high H3 responses in the third 
category (2.5–3.5; n = 3272), albeit in combination with markedly increased H1 signals compared to lower cate-
gories. The fourth category (3.5–4; n = 1348) comprised individuals with the highest antibody diversity and reac-
tivity against H1.09. Pandemic, seasonal H1, and seasonal H3 antigens were approximately equally strong in this 
group, partly reflecting saturated luminescence signals in the assay. A total of 161 individuals (2.1% of the total 
population; 0.8% and 9.9% of diversity category 3 and 4, respectively) had saturated fluorescence values for H1.09 
and all four seasonal antigens; all but one of these individuals were sampled after pandemic onset.
Analysis of Broad responders. Based on the high and broad signals in the fourth category (3.5 < ASDI 
≤ 4.0), we designated subjects in this category as ‘broad responders’, i.e. individuals showing serological responses 
to between 3.5 and 4 antigens. Approximately half of the individuals in the fourth category (52%, n = 702) were 
from the northern hemisphere (Canada, USA, Sweden, United Kingdom and Japan) and had been sampled after 
pandemic onset (Table 1).
Consistent with our hypothesis, we observed a gradual elevation in heterosubtypic reactivity against avian 
influenza antigens with increasing diversity categories (Fig. 2, green). Broad responders (3.5 < SDI ≤ 4.0) showed 
the highest reactivity against avian antigens, which was most pronounced for H9, followed by H7; reactivity to H5 
antigens remained low (Fig. 2, green). However, some cross reactivity was found in each diversity category, and 
Continent Country Country totals Row totals Pandemic onset1,2 Sampling period (year/week)
Diversity index categories
1 2 3 4
0–1.5 1.5–2.5 2.5–3.5 3.5–4
North America
Canada 913
444 Pre 08/40–09/32 6.8 34.7 45 13.5
469 Post 09/33–10/26 1.1 17.1 48 33.9
Mexico (central) 579
272 Pre 09/26–09/45 21 40.4 32.7 6.2
307 Post 09/46–10/24 8.1 41.7 36.2 14
Mexico (northern) 432
432 Pre 09/01–09/044 18.8 50.9 26.6 3.7
0 Post NA
USA 520
130 Pre 09/28–09/40 0.8 24.6 47.7 26.9
390 Post 09/41–10/26 0.3 8.7 38.7 52.3
Europe
The Netherlands 559
188 Pre 09/27–09/45 1.6 46.8 40.4 11.2
371 Post 09/46–10/30 0.5 32.1 50.1 17.3
Portugal 479
130 Pre 09/28–09/40 13.8 54.6 28.5 3.1
349 Post 09/41–10/23 5.2 33.8 44.4 16.6
Sweden 868
526 Pre 08/40–09/40 2.5 46.4 44.3 6.8
342 Post 09/41–10/22 0.3 20.2 49.1 30.4
Switzerland 637
180 Pre 09/23–09/40 3.3 31.1 52.2 13.3
457 Post 09/41–10/34 3.5 33.5 50.3 12.7
UK 568
190 Pre 09/27–09/45 7.9 39.5 40 12.6
378 Post 09/46–10/30 2.6 27.5 47.4 22.5
Asia
India 474
120 Pre 09/28–09/40 4.2 31.7 51.7 12.5
354 Post 09/41–10/25 3.4 34.5 48.3 13.8
Japan 530
140 Pre 09/27–09/40 1.4 21.4 51.4 25.7
390 Post 09/41–10/26 0.3 13.6 47.7 38.5
Lebanon 337
337 Pre 09/02–09/44 11.3 49.3 34.4 5
Post NA
Africa South Africa 276
248 Pre 09/29–10/15 12.1 48 35.1 4.8
28 Post 10/16–10/21 42.9 42.9 14.3
South America Argentina 412
Pre NA
412 Post 09/27–10/16 6.6 37.1 43.4 12.9
Total range of 
study weeks: 08/40–10/34
Totals per 
pandemic period pre: 3337 post: 4247
Totals per 
diversity category 416 2548 3272 1384
Total 7584
Table 1. Characteristics of study population and number of samples submitted per country and time 
period. 1Pandemic onset of A(H1N1)pdm09; 2pre- and post pandemic onset of circulation of A(H1N1)pdm09 
per respective country, percentages are represented within pandemic period; NA: not available. Diversity index 
categories reflect percentage of individuals within the respective category.
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we found statistically significant Spearman’s rank correlation coefficients between diversity indices and AI HA1 
reactivities (0.25–0.29 for H5, 0.35 for H7 and 0.42–0.43 for H9; all p < 10^−15). Similarly, some heterosubtypic 
reactivity against ancient and older pandemic human strains (H1.33 and H2.57) was detected with increasing 
diversity categories (Fig. 2, red).
Explaining heterosubtypic reactivity by serological responses to recent seasonal and pandemic 
strains. We performed a multivariable linear regression analysis using reactivity to human seasonal and 
recent pandemic influenza HA1 antigens as explanatory variables to explore the relationship between serological 
responses to AI antigens and infection with recent human influenza virus strains (Table 2). Antibody reactivities 
to most included antigens (i.e. explanatory variables) were able to explain the variation observed in H7- and H9 
signals to some extent (Table 2), as these reactivities predominantly tended to be positively correlated (Table 2). 
However, antibody reactivities to the most recent human influenza strains H1.09 and H3.07 had a larger relative 
effect on the variation of H7 and H9 signals compared to signals against other antigens, indicating that recent 
infection with these viruses can explain part of the low-level heterosubtypic antibody reactivity to AI virus anti-
gens. Nevertheless, the models could only explain between 28% and 38% of observed variation in H7 and H9 
avian responses, suggesting a more complex relationship (Table 2). Multicollinearity between explanatory vari-
ables was not an issue as variance inflation factors for all explanatory variables in all models remained below 10 
(range: 1.41–3.59). Likewise, testing model assumptions revealed no overt violations of homoscedasticity and 
deviation from normality of residuals after log-transformation. Regression analysis was not attempted for H5, 
given the low antibody signals.
The influence of A(H1N1)pdm09 on the level of cross-reactive antibodies. To further exam-
ine whether exposure to the novel pandemic influenza strain A(H1N1)pdm09 was associated with increased 
cross-reactivity, we divided the data set into two periods of before (n = 3337) and after pandemic onset (n = 4247) 
(Table 1). We observed a clear shift in proportion of broad responders (category 4) towards higher diversity cat-
egories after pandemic onset (Chi-squared test, p-value < 0.001) (Table 3a). Proportions of H1.09-seropositive 
individuals gradually increased with increasing diversity index categories for pre- and post-pandemic periods. 
Within each category, changes in proportions between pandemic periods according to seropositivity status were 
significant for all but the lowest category, which could not be tested due to too few observations (Chi-squared 
Figure 1. (a) Overall antibody reactivity against different antigens for the entire study period (week 40, 2008 
to week 34, 2010) including all countries. (b) Development of A(H1N1)pdm09 over time for all countries 
combined. Pandemic onset and -course per country were previously described in de Bruin et al.30. Both y-axes 
represent fluorescence values on a log10-scale.
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Figure 2. Serological profiles based on adapted Shannon diversity index (ASDI) categories. Recent seasonal 
influenza virus antigens were used to calculate ASDI per individual to summarize individual antibody profiles 
in one measure (blue). Assumed cross-reactive antibody responses are depicted in red (ancient- and older 
pandemic influenza virus strains) and green (avian influenza virus strains). Fluorescence values representing 
serological reactivity per antigen (x-axis) are shown on a log10-transformed y-axis.
Outcome Intercept
Estimates with standard errors (SE) Adjusted 
R2H1.99 H3.03 H1.07 H3.07 H1.09
H7.03 5.99 -0.03 0.05 0.05 0.16 0.25 0.28
SE 0.14 0.013 0.011 0.013 0.012 0.009
*** * *** *** *** ***
H9.99 3.90 -0.12 0.14 0.29 0.35 0.38
SE 0.15 0.014 0.014 0.011 0.010
*** *** *** *** ***
H9.07 4.22 -0.05 0.08 0.11 0.16 0.32 0.37
SE 0.15 0.013 0.011 0.014 0.013 0.011
*** *** *** *** *** ***
Table 2. Regression coefficients calculated on log2-transformed data spanning pre- and post-pandemic 
periods. Outcome refers to reactivity against heterologous antigens on which serological responses against 
recent human influenza virus antigens were regressed (explanatory variables). The number of asterisks indicates 
level of significance. Significance codes: 0 ***0.001 **0.01 *0.05.1.
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test, p-values < 0.001, Table 3b). The vast majority of H1.09-seropositive individuals were sampled in the 
post-pandemic period (3.3% pre-, versus 29% post pandemic, Table 3b).
Next, we only included data from persons sampled after the pandemic onset in the analysis, to ensure that 
serological responses were truly triggered by H1.09 infection or vaccination (Table 3b). With exception of the 
lowest ASDI category that only comprised four individuals in the H1.09 positive category (Table 3b), within 
higher ASDI categories, we generally observed higher heterosubtypic antibody responses among H1.09-positive 
individuals compared to negative ones (Fig. 3). Post-pandemic onset, 57% of broad responders (highest diversity 
category 4) were seropositive for H1.09 (Table 3b). In this category, we also observed significantly higher levels 
of H7 and H9 antibodies compared to H1.09-negative persons (Fig. 3; Wilcoxon rank sum test, p-value < 0.001).
Heterosubtypic reactivity and its consequences of for seroprevalence studies of avian influ-
enza in humans. When estimating the proportion of individuals with titers of approximately higher than 
80 against AI antigens (based on an arbitrary cut-off applied to fluorescence values as described in the Methods 
section), we found that overall, about 1% (n = 53–80) of individuals had antibody titers > 80 for H5 antigens, and 
4.3% (n = 329), 9.5% (n = 720) and 7.5% (n = 571) of individuals showed titers > 80 to H7.03, H9.99 and H9.07, 
respectively. The majority thereof were sampled in the post-pandemic period [1% (n = 49–76), 6.5% (n = 276), 
13.7% (n = 580) and 10.8% (n = 460), respectively, Fig. 4].
Discussion
In this study, we investigated serological profiles against human influenza virus subtypes in healthy humans 
from around the world and studied associations between serological responses to seasonal influenza viruses and 
heterosubtypic reactivity, defined as presence of antibodies to influenza viruses that have not circulated among 
humans. A validated microarray platform35 comprising recombinant HA1 proteins, i.e. the globular head of 
the HA, was used to provide standardized serological profiles to a range of influenza A virus antigens in this 
population-based study.
The highest antibody titers were observed against H3-virus antigens [A(H3.03), A(H3.07)]. This subtype 
emerged in the human population in 1968, and in 1977, subtype A(H1N1) re-emerged and co-circulated with 
A(H3N2) until 200932. Given the assumed range of birth years of our study population (between 1968 and 1990), 
a significant proportion of individuals was probably primed (i.e. experienced their first influenza infection) by 
subtype A(H3N2) influenza viruses. These findings are consistent with the observation of original antigenic 
sin36,37, a phenomenon by which an individual’s first influenza infection imprints a high life-long specific anti-
body titer in that individual. Under this hypothesis, infections with recent strains thereby serve as a booster for 
antibodies to the ‘original’ strain, whereas specific antibodies to the recent strain itself may be detected at low or 
moderate levels.
A number of serosurveillance studies conducted on high risk groups revealed serological evidence for avian 
viruses23–25,38–40, although the possibility of cross-reactive antibodies for most studies was raised in a commen-
tary article41. The level of seropositivity may also be influenced by the type of assay and respective cut off levels 
used (e.g. hemagglutination inhibition- (HI), microneutralization (MN)- or pseudotype-based assay)42. In this 
study, we investigated cross-reactive antibodies to AI virus antigens in the general population, and its relation to 
Diversity index category
1 2 3 4* Total
ASDI range: 0–1.5 1.5–2.5 2.5–3.5 3.5–4
pre postPandemic onset: pre post pre post Pre post pre post
A) Per diversity category & pandemic period
N 298 118 1403 1145 1319 1953 317 1031
3337 4247% pre/post, by 
diversity category 71.6 28.4 55.1 44.9 40.3 59.7 23.5 76.5
% in diversity 
category, by pre/
post
8.9 2.8 42 27 39.5 46 9.5 24.3 44 (100%) 56 (100%)
B) H1.09 antibody reactivity
N negative 298 114 1395 1067 1265 1391 270 443 3228 3015
% 100 96.6 99.4 93.2 95.9 71.2 85.2 43.0 96.7 71
N positive 0 4 8 78 54 562 47 588 109 1232
% 0 3.4 0.6 6.8 4.1 28.8 14.8 57 3.3 29
N within 
diversity category 416 2548 3272 1348 7584
Total % 5.5 33.6 43.1 17.8 100
Total N H1.09-
negative/ positive 
(%)
6243 (82.3) 1341 (17.7)
Table 3. (A) Number and proportions of individuals per category based on adapted Shannon diversity index 
(ASDI) versus pre- and post-pandemic periods. (B) Number and proportion of H1.09-positive and -negative 
individuals per diversity category before (n = 3337) and after (n = 4247) pandemic onset, respectively. 
*Category of ‘Broad responders’, defined as showing the highest antibody diversity across recent seasonal 
human influenza viruses (H1.99, H1.07, H3.03, H3.07), expressed by the Adapted Shannon diversity indices 
(ASDI).
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Figure 3. Antibody profiles of samples collected after pandemic onset, stratified according to adapted 
Shannon diversity index (ASDI) and seropositivity status to A(H1N1)pdm09. 
Figure 4. Estimated proportions of individuals with titers to avian influenza virus antigens of higher than 
approximately 80. Proportions are presented for the total study period and split according to pre- and post 
pandemic periods. Reactivity to the three H5 antigens is combined.
www.nature.com/scientificreports/
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antibody diversity against recent human influenza virus strains by developing an adapted Shannon diversity index 
(ASDI) as a summary measure describing both antibody diversity and total antibody concentration. Consistent 
with our hypothesis, we demonstrated a positive association between increasing antibody diversity and hetero-
subtypic reactivity against AIV antigens. These observations are consistent with previous publications that have 
found raised antibody titers to AI antigens in the general population28–43,44. A population-based studies on het-
erosubtypic immunity of intravenous immunoglobulins (IVIG) from blood donors from Australia, Malaysia and 
Europe clearly showed binding of heterosubtypic antibodies against H9 and H5, but negligible binding against H7 
subtypes by immunoblotting. In IVIG formulations from all regions neutralizing ability could be confirmed for 
H5 subtypes using cell culture45. Consistent with our findings, a study conducted in the general population from 
rural and urban locations in Vietnam, using the same protein microarray, reported similarly elevated antibody 
titers to H9 and to a lower extent H7 and H5 antigens33. Similarly, depending on the cut-off used (ranging from 
80 to 20), 0.25% to 9.4% and 1.8% (cut-off of 20) of the general population in Wuhan, China, tested seroposi-
tive for H9 and H7 by HI-assay, respectively43. Serological evidence for antibodies to influenza A(H5N1) was 
also detected in the Italian general population by single radial hemolysis, but could not be confirmed by HI- or 
MN-assay44.
With the onset of the A(H1N1) pandemic, pre-existing immunity and heterosubtypic antibody responses to 
AI viruses in the general population became of significant interest10–12. For this reason, we focussed our analysis 
of cross-reactive antibody patterns on this cohort, to perform inference on AI antibody concentrations only, 
and to describe associations with other covariates. During the unfolding of the pandemic, overall cross-reactive 
responses to AI viruses increased. Multiple linear regression analysis suggested that H1.09 responses could 
explain part of this heterosubtypic reactivity but there was considerable heterogeneity in antibody profiles, with 
persons responding differently to similar challenges, most likely due to differences in exposure history. Therefore, 
the history of exposures to human seasonal and pandemic influenza exposures, natural or vaccine-induced, can 
influence levels of antibodies that bind to animal viruses46.
The present study design had some limitations that need to be weighed when looking at the effects of human 
influenza infections on heterosubtypic antibody response. First, we were unable to discern whether serological 
reactivity against H1.09 was triggered by natural infection or by vaccination with the novel pandemic strain, as 
the onset of circulation of A(H1N1) pdm09 coincided with the beginning of vaccination campaigns in the major-
ity of participating countries30. A recent study in pregnant women demonstrated that immune response elicited 
by vaccination to A(H1N1)pdm09 was significantly higher than after natural infection. This observation was also 
reflected in newborns of vaccinated mothers, with 89.5% showing antibodies to the pandemic strain, compared 
to 15.8% of infants born to naturally infected mothers47. Second, a limitation is that all study participants were of 
childbearing age. Although this subset of the general population represents an unbiased sample, extrapolation of 
these conclusions to the general population, including young infants and older age groups, should be made with 
caution. The assumption that our study participants were between 20 and 40 years of age, seemed appropriate. 
Estimated mean ages of women at childbearing ranged from 26.3 to 30.9 between 2005 and 2010 for the partici-
pating countries48. However, we cannot fully exclude that a small proportion of individuals was older and experi-
enced natural infection with H2N2, a subtype that may generate additional cross-reaction to AI. Furthermore, no 
information on poultry exposure was available. Given the near global distribution of AI, we cannot exclude that 
part of the study population might have been exposed to and possibly infected with AI viruses. However, only five 
participating countries (the Netherlands, USA, Canada, India, Japan) reported AI outbreaks (H5, H7) in birds 
during the period of our study49.
Finally, whereas the microarray platform serves as an excellent screening tool to investigate population expo-
sure to various influenza virus HA1s in a standardized fashion, it cannot provide information on functionality 
of heterosubtypic antibodies against avian antigens detected in our study (i.e. neutralizing ability), neither can 
it measure cross-reactive antibodies against the HA2 stem region of the HA. Previous experiments using the 
entire recombinant HAs of different subtypes in the microarray platform had low discriminatory ability, as the 
HA2 is more conserved between different influenza virus subtypes. Using HA1s, therefore, provides a better 
resolution of antibodies targeting the more variable globular head of the HA, thereby allowing subtype discrim-
ination. Although we cannot directly generalize antibody reactivities against the HA1 to the entire HA, we pre-
viously showed good correlation between antibody titers measured by HI and by microarray HA1 proteins33–35. 
Longitudinal studies examining heterosubtypic responses using functional assays would shed light on this issue. 
This is in fact the major limitation in all human serological studies of AI - it is unknown whether assay results 
correlate to any level of severity or protection from infection. Given the pandemic potential of AI virus subtypes, 
investigating the protective effect of cross-reactive responses to AI viruses in the general population would aid 
pandemic preparedness by providing information on herd immunity50. Ascertaining, whether antibody responses 
against avian influenza viruses reflect true exposure or cross-reactivity, remains a challenge. To address this issue 
further, establishing antibody profiles from humans exposed to avian influenza viruses during AI outbreaks could 
be considered, while also systematically expanding population-level serological studies by including exposure 
and vaccination history. Such an approach would allow studying kinetics of low-level heterosubtypic antibody 
responses and comparison of serological profiles in high- versus low risk populations, thereby potentially aiding 
unbiased interpretation of such findings. For these purposes, the microarray platform could serve as a broad first 
screening assay, which could be followed by additional serological tests, such as the HI- or MN-assay to ascertain 
functionality of the detected antibodies.
Methods
Study population. In a study conducted to monitor the progression of the A(H1N1)pdm09 in differ-
ent parts of the world, 13 countries from five continents contributed more than 7000 anonymized, filter cards 
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containing dried blot spots from heel prick sampling30 (Table 1) through neonatal screening programs. This 
collection method, originally implemented to test for hereditary diseases in new-borns, can also be used to meas-
ure maternal antibodies conferred via the placenta51. As samples could only be collected when anonymized, we 
assumed the age of the mothers to be between 20 to 40 years, translating to birth years ranging from 1968 to 1990. 
We furthermore hypothesized that study subjects in our data set reflect a segment of the general population with 
unknown prior poultry exposure, thus providing an unbiased systematic population sample.
Ethical approval. As previously described in de Bruin et al.30, participants were included in the study in 
accordance with local medical ethical rules. Samples were collected within neonatal screening programs and 
parents provided informed consent for using residual samples (anonymized) for research purposes. The study 
was approved by the Japanese Institutional Review Board of the Sapporo City Institute of Public Health (ref-
erence number 09-010) and the American NYS DOH Institutional Review board (protocol number #09-045). 
Participating laboratories collected 10 randomly selected anonymized filter paper cards per week, concordant 
with regulations of local ethical committees.
Protein microarray technique. IgG levels against different human and avian influenza HA types were 
measured using a protein microarray platform as described previously30–35. Briefly, recombinant proteins of 
the HA1 part of HA of different influenza virus subtypes (see supplementary material S2) were printed onto 
nitrocellulose-coated glass slides (64pad, Oncyte Avid, Grace Biolabs, Bend, USA) using a non-contact Piezorray 
spotter (Perkin Elmer, Waltham, USA). Subsequently, dried blood spots were eluted as described previously 
and samples were tested at a 1:80 dilution30. A Dylight649-labelled goat-anti-human IgG (Fc-fragment specific, 
Jackson ImmunoResearch) was used to bind to serum antibodies and fluorescence was quantified by means of 
a microarray scanner (ScanArray, Perkin Elmer). The protein microarray technique allows simultaneous and 
standardized detection of antibodies against different influenza subtypes in a minute serum quantity. It has also 
been used to measure influenza IgG titers in humans35.
Data analysis. Data analysis was performed in R (version 3.1.0, R Statistical Computing, Vienna, Austria). 
For all statistical analyses, a p-value of less than 0.05 was considered statistically significant. All samples were 
normalized to a mean background fluorescence of 5000. Correction for day-to-day variation between microar-
ray slides was achieved based on H1.09 signals against an international standard positive control as described 
before30.
For exploratory data analysis, overall fluorescence values between different antigens were compared using the 
Wilcoxon signed rank test. To characterize antibody profiles and study possible profile-specific heterosubtypic 
reactivities against AI antigens, we summarized individual serological responses against multiple antigens using 
the Shannon diversity index, which is a measure frequently applied in ecological studies to quantify biodiversity 
of species within habitats (see supplementary material S3). For our purpose, we adapted the Shannon diver-
sity index (ASDI) so that we could detect both diversity and magnitude of an antibody response (a traditional 
Shannon diversity index only describes magnitude). To achieve this effect, we included a dummy serological 
response with a fluorescence value of 50.000 to ensure that low-and-broad antibody profiles receive a low ASDI 
score (see supplementary material S3). Only seasonal human influenza antigens that circulated in the 10 years 
prior to the sample collection were included in the ASDI calculation (H1.99, H1.07, H3.03, H3.07; Table S1). The 
most recent pandemic strain H1.09 was not included in the ASDI calculation, so that we could investigate its 
effect on antibody profiles within ASDI categories. The dummy strain’s contribution was subtracted off, and the 
ASDI can thus be thought of as the number of strains to which an individual has a high antibody response; the 
maximum diversity being 4.0. For the purposed of presentation, we divided the ASDI range into four arbitrary 
categories ranging from ‘0–1.5’, ‘1.5–2.5’, ‘2.5–3.5’, and ‘3.5–4’. Associations between ASDI and avian fluorescence 
signals were evaluated using a Spearman correlation coefficient.
We used R packages ‘psych’52 and ‘ggplot2’53 for exploratory analysis and to create figures, respectively. Package 
‘MASS’54 was used for a multivariable log-log linear regression model (with backward elimination using func-
tion ‘stepAIC’) to investigate whether antibody reactivity against recent human antigens (H1.99, H1.07, H3.03, 
H3.07, H1.09) could explain serological reactivity against avian antigens. Repeating the analysis using a ‘forward 
selection’ algorithm yielded the same results. The full model included all recent human H1 and H3 antigens as 
explanatory variables. Final models included only significant explanatory variables presented in this table. R 
package ‘car’55 was used to calculate the variance inflation factor to check for multicollinearity between explana-
tory variables.
For comparison of mean ranks of fluorescence levels per antigen during the A(H1N1) pandemic of 2009/2010, 
we used the non-parametric Wilcoxon Rank-Sum test with continuity correction on data stratified by pre- and 
post-pandemic sampling periods. For this, “time of pandemic onset” was selected based on country-specific 
pandemic curves as shown in de Bruin et al.30 (Table 1). To determine a cut-off for the pandemic H1.09 HA1 
antigen signals, we used H1.09 data of samples collected before the official onset of the pandemic in April 2009. 
The cut-off was established using mean fluorescence levels plus three standard deviations. Using this cut-off, we 
reported proportions of H1.09-seropositive individuals within ASDI categories.
To investigate the effect of the A(H1N1)pdm09 on the proportions of broad responders, a Pearson’s 
chi-squared test was used to test for changes in proportions before and after pandemic onset.
As samples of the study population were tested in a one-point dilution (1:80), we used this arbitrary cut off 
to approximate proportions of individuals with an estimated antibody titer of higher than 80 to avian antigens. 
Based on prior studies35, a fluorescence cut-off point of ~30.000 corresponds to an antibody titer of higher than 
approximately 80.
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